- Title: Subtitle
- SU2C-SARC032: A phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft tissue sarcoma
- Creators
- Yvonne Marie Mowery - Duke Medical CenterKarla V. Ballman - Cornell UniversityRichard F. Riedel - Duke Medical CenterBrian E. Brigman - Duke UniversitySteven Attia - Mayo Clinic in FloridaChristian Frederick Meyer - Johns Hopkins HospitalScott Schuetze - University of Michigan–Ann ArborMelissa Amber Burgess - University of PittsburghBartosz Chmielowski - Los Angeles Medical CenterMark Andrew Dickson - Memorial Sloan Kettering Cancer CenterLee P. Hartner - University of PennsylvaniaMohammed M. Milhem - University of IowaGabriel Tinoco - The Ohio State UniversityBrian Andrew Van Tine - Washington University in St. LouisAndrew J. Wagner - Dana-Farber Cancer InstituteDenise K. Reinke - Sarcoma Alliance for Research through CollaborationDavid G. Kirsch - Duke Medical Center
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.36(15_suppl), pp.TPS11588-TPS11588
- DOI
- 10.1200/JCO.2018.36.15_suppl.TPS11588
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2018
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984363295502771
Abstract
SU2C-SARC032: A phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft tissue sarcoma
Journal of clinical oncology, Vol.36(15_suppl), pp.TPS11588-TPS11588
05/20/2018
DOI: 10.1200/JCO.2018.36.15_suppl.TPS11588
Details
Metrics
8 Record Views